Search results
Results From The WOW.Com Content Network
The ratio of the absorbance at 260 and 280 nm (A 260/280) is used to assess the purity of nucleic acids. For pure DNA, A 260/280 is widely considered ~1.8 but has been argued to translate - due to numeric errors in the original Warburg paper - into a mix of 60% protein and 40% DNA. [6] The ratio for pure RNA A 260/280 is ~2.0. These ratios are ...
Canine coronavirus strain NTU336/F/2008. Canine coronavirus (CCoV) is an enveloped, positive-sense, single-stranded RNA virus which is a member of the species Alphacoronavirus 1. It causes a highly contagious intestinal disease worldwide in dogs. [2] The infecting virus enters its host cell by binding to the APN receptor. [3]
An mRNAvaccine is a type of vaccine that uses a copy of a molecule called messenger RNA (mRNA) to produce an immune response. [ 1 ] The vaccine delivers molecules of antigen -encoding mRNA into cells, which use the designed mRNA as a blueprint to build foreign protein that would normally be produced by a pathogen (such as a virus) or by a ...
A recent study in the journal Vaccine found that vaccine hesitancy among dog owners contributed to opposition to inoculation for canine-borne diseases, such as rabies.
A nucleoside-modified messenger RNA (modRNA) is a synthetic messenger RNA (mRNA) in which some nucleosides are replaced by other naturally modified nucleosides or by synthetic nucleoside analogues. [ 1 ] modRNA is used to induce the production of a desired protein in certain cells. An important application is the development of mRNA vaccines ...
Ribonucleic acid (RNA) is a polymeric molecule that is essential for most biological functions, either by performing the function itself (non-coding RNA) or by forming a template for the production of proteins (messenger RNA). RNA and deoxyribonucleic acid (DNA) are nucleic acids. The nucleic acids constitute one of the four major ...
RNA therapeutics are a new class of medications based on ribonucleic acid (RNA). Research has been working on clinical use since the 1990s, with significant success in cancer therapy in the early 2010s. [ 1 ] In 2020 and 2021, mRNA vaccines have been developed globally for use in combating the coronavirus disease (COVID-19 pandemic). [ 2 ]
The first use of RNA for vaccination purposes was described in 1993 by Frédéric Martinon, Pierre Meulien and colleagues [10] [11] and in 1994 by X. Zhou, Peter Liljeström, and colleagues in mice. [12] [11] Martinon demonstrated that a cellular immune response was induced by vaccination with an RNA vaccine. [11]